Relapse and aggressive progression of melanoma occurs in most of the patients after 5–7 months of treatment with BRAF inhibitors due to re-activation of MAPK and/or cooperation of PI3K and other alternative signaling pathways [4, 5, 35]. Here, BRAF is linked to melanoma.